213 related articles for article (PubMed ID: 11399688)
21. Comparison of inhaled salmeterol and individually dose-titrated slow-release theophylline in patients with reversible airway obstruction. European Study Group.
Paggiaro PL; Giannini D; Di Franco A; Testi R
Eur Respir J; 1996 Aug; 9(8):1689-95. PubMed ID: 8866596
[TBL] [Abstract][Full Text] [Related]
22. [efficacy and safety of salmeterol in long-term therapy in patients with chronic obstructive airway diseases].
Beeh KM; Wiewrodt R; Salem AE; Buhl R
Pneumologie; 2000 Jun; 54(6):225-31. PubMed ID: 10934892
[TBL] [Abstract][Full Text] [Related]
23. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.
D'Alonzo GE; Nathan RA; Henochowicz S; Morris RJ; Ratner P; Rennard SI
JAMA; 1994 May; 271(18):1412-6. PubMed ID: 7909853
[TBL] [Abstract][Full Text] [Related]
24. Salmeterol versus theophylline in the treatment of asthma.
Pollard SJ; Spector SL; Yancey SW; Cox FM; Emmett A
Ann Allergy Asthma Immunol; 1997 May; 78(5):457-64. PubMed ID: 9164358
[TBL] [Abstract][Full Text] [Related]
25. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD).
Boyd G; Morice AH; Pounsford JC; Siebert M; Peslis N; Crawford C
Eur Respir J; 1997 Apr; 10(4):815-21. PubMed ID: 9150318
[TBL] [Abstract][Full Text] [Related]
26. Long-term treatment of asthmatic patients with salmeterol vs slow-release theophylline.
Nutini S; Martini T; Righi R
Respir Med; 1998 Apr; 92(4):683-90. PubMed ID: 9659537
[TBL] [Abstract][Full Text] [Related]
27. Salmeterol versus slow-release theophylline in patients with reversible obstructive pulmonary disease.
Taccola M; Bancalari L; Ghignoni G; Paggiaro PL
Monaldi Arch Chest Dis; 1999 Aug; 54(4):302-6. PubMed ID: 10546469
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular safety of salmeterol in COPD.
Ferguson GT; Funck-Brentano C; Fischer T; Darken P; Reisner C
Chest; 2003 Jun; 123(6):1817-24. PubMed ID: 12796155
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease.
Cazzola M; Centanni S; Boveri B; Di Marco F; Santus P; Matera MG; Allegra L
Respiration; 2001; 68(5):452-9. PubMed ID: 11694805
[TBL] [Abstract][Full Text] [Related]
30. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
[TBL] [Abstract][Full Text] [Related]
31. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
Appleton S; Smith B; Veale A; Bara A
Cochrane Database Syst Rev; 2000; (2):CD001104. PubMed ID: 10796594
[TBL] [Abstract][Full Text] [Related]
32. Oral bambuterol compared to inhaled salmeterol in patients with partially reversible chronic obstructive pulmonary disease.
Cazzola M; Calderaro F; Califano C; Di Pema F; Vinciguerra A; Donner CF; Matera MG
Eur J Clin Pharmacol; 1999 Jan; 54(11):829-33. PubMed ID: 10027655
[TBL] [Abstract][Full Text] [Related]
33. Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers.
Chapman KR; Ringdal N; Backer V; Palmqvist M; Saarelainen S; Briggs M
Can Respir J; 1999; 6(1):45-51. PubMed ID: 10202220
[TBL] [Abstract][Full Text] [Related]
34. Bronchodilator therapy in chronic obstructive pulmonary disease.
Manning HL
Curr Opin Pulm Med; 2000 Mar; 6(2):99-103. PubMed ID: 10741767
[TBL] [Abstract][Full Text] [Related]
35. The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies.
Davies B; Brooks G; Devoy M
Respir Med; 1998 Feb; 92(2):256-63. PubMed ID: 9616522
[TBL] [Abstract][Full Text] [Related]
36. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
Bateman ED; van Dyk M; Sagriotis A
Pulm Pharmacol Ther; 2008; 21(1):20-5. PubMed ID: 17118684
[TBL] [Abstract][Full Text] [Related]
37. Inhaled salmeterol or oral theophylline in nocturnal asthma?
Selby C; Engleman HM; Fitzpatrick MF; Sime PM; Mackay TW; Douglas NJ
Am J Respir Crit Care Med; 1997 Jan; 155(1):104-8. PubMed ID: 9001297
[TBL] [Abstract][Full Text] [Related]
38. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
Pearlman DS; Stricker W; Weinstein S; Gross G; Chervinsky P; Woodring A; Prillaman B; Shah T
Ann Allergy Asthma Immunol; 1999 Mar; 82(3):257-65. PubMed ID: 10094216
[TBL] [Abstract][Full Text] [Related]
39. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
FitzGerald JM; Boulet LP; Follows RM
Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
[TBL] [Abstract][Full Text] [Related]
40. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD.
Brusasco V; Hodder R; Miravitlles M; Korducki L; Towse L; Kesten S
Thorax; 2003 May; 58(5):399-404. PubMed ID: 12728159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
